Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Departure of Directors or Certain Officers
19 Mar 24
8-K
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
27 Feb 24
8-K/A
Departure of Directors or Certain Officers
5 Feb 24
8-K
Departure of Directors or Certain Officers
5 Feb 24
8-K
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
19 Jan 24
8-K
Aclaris Therapeutics Provides Corporate Update
19 Dec 23
8-K
Regulation FD Disclosure
13 Nov 23
8-K
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
6 Nov 23
8-K
Regulation FD Disclosure
18 Sep 23
8-K
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
7 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
8 May 23
424B5
Prospectus supplement for primary offering
23 Feb 23
S-8
Registration of securities for employees
10 May 22
424B5
Prospectus supplement for primary offering
10 Jun 21
424B5
Prospectus supplement for primary offering
8 Jun 21
S-3ASR
Automatic shelf registration
20 May 21
S-8
Registration of securities for employees
7 May 21
424B5
Prospectus supplement for primary offering
20 Jan 21
S-3MEF
Registration of additional securities for an S-3
20 Jan 21
424B5
Prospectus supplement for primary offering
19 Jan 21
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
20 Apr 23
DEF 14A
Definitive proxy
20 Apr 23
PRE 14A
Preliminary proxy
10 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEFA14A
Additional proxy soliciting materials
23 Apr 20
Other
EFFECT
Notice of effectiveness
30 Apr 20
CORRESP
Correspondence with SEC
23 Apr 20
UPLOAD
Letter from SEC
19 Mar 20
CT ORDER
Confidential treatment order
9 May 19
CT ORDER
Confidential treatment order
20 Dec 18
CT ORDER
Confidential treatment order
4 Sep 18
CT ORDER
Confidential treatment order
17 May 18
CT ORDER
Confidential treatment order
14 Nov 17
EFFECT
Notice of effectiveness
1 Dec 16
EFFECT
Notice of effectiveness
14 Nov 16
Ownership
4
Neal Walker
3 Apr 24
4
Neal Walker
5 Mar 24
4
Joseph Monahan
5 Mar 24
4
Kevin Balthaser
5 Mar 24
4
Andrew Kenneth William Powell
5 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
MILLENNIUM MANAGEMENT LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24